Introduction
============

The two competing theories for the origin of life (metabolism-first and gene-first) suggest that abiotic chemical reactions were the progenitors of biotic life. These abiotic chemical reactions ultimately formed the basis for metabolism and provided building blocks for the synthesis of both RNA and protein. Over millions of years, cells formed and evolved and, in doing so, generated the diversity of life we observe today. Across phylogeny, the core metabolic pathways necessary for life have been well conserved ([@B171]). In these core pathways, anabolism and catabolism generate a multitude of different metabolites. The potential chemical reactions in which these metabolites can participate greatly exceed cellular metabolic requirements. Therefore, the cell has evolved diverse mechanisms to control these "extra-metabolic" compounds to limit their toxicity or the damage that they impart upon macromolecular structures via non-enzymatic reactions within the cell ([@B53]). While cells have evolved means of controlling these "extra-metabolic" compounds, it is thought that accumulation of the resultant damage may be a prototypic driver of aging ([@B74]).

Despite the constant possibility of damage due to their own metabolism, bacteria have survived and evolved to adapt to various niches. However, these environments are rarely constant outside of a laboratory setting, and bacteria will often face adverse conditions. In these niches, one of the major challenges is acquisition of nutrients necessary to grow and divide. While some nutrients like carbon may be readily abundant, other nutrients can be scarce, such as iron sequestered by a host ([@B87]). These conditions may change suddenly, so the bacteria must respond accordingly or perish. It is well established that cells respond to environmental challenges with appropriate regulation of their transcriptional and translational programs ([@B75]). Whereas transcription and translation are time- and energy-intensive processes, post-translational control over the function of existing proteins can rapidly alter cellular physiology and permit fitness or survival in otherwise suboptimal or lethal conditions ([@B31]; [@B132]). While small ligands may allosterically regulate proteins, diverse covalent chemical modifications of the existing proteome also occur; these may or may not be reversible ([@B141]). Researchers have identified hundreds of chemical modifications of the proteome; these are called post-translational modifications (PTMs). These PTMs can occur on a variety of protein residues and understanding how these modifications affect protein structure and function and whether they interact with one another is critical to generating a complete regulatory picture of the cell.

Many PTMs occur on lysines within proteins, including methylation ([@B109]), propionylation ([@B32]), butyrylation ([@B32]), crotonylation ([@B216]; [@B188]), succinylation ([@B274]), malonylation ([@B55]; [@B170]), glutarylation ([@B217]), 2-hydroxyisobutyrylation ([@B44]), pupylation ([@B13]), and *N*𝜀-lysine acetylation, which is becoming recognized as a prominent modification that is conserved across phylogeny ([@B100]; [@B34]). While lysine acetylation is best understood as an activating modification of eukaryotic histones ([@B80]), extensive study into the role of lysine acetylation in bacteria only began about a decade ago. Acetylation of certain lysines may have a clear consequence, such as inhibition of enzyme activity due to modification of an active site ([@B154]), but the functional importance or lack thereof of many acetyllysine modifications are more difficult to discern. To uncover the role of lysine acetylation in these unclear cases, it is helpful to use a model bacterium (e.g., *Escherichia coli*) with a vast knowledgebase of pathways, protein structure-function relationships, and physiology.

This review will detail what we know concerning lysine acetylation in bacteria with some attention paid to eukaryotic acetylation for context. We will begin by describing the different types of acetylation, the mechanisms that result in acetylation of lysines, and some known effects of lysine acetylation on protein function. We will discuss the importance of mass spectrometry to identify and quantify acetylated proteins. Furthermore, we will explore the possibility that acetylation could be a driver of protein and organismal evolution. Finally, with our deepening understanding of acetylation, we will discuss a possible future for this new field.

Acetylation -- From Small Molecules to Proteins
===============================================

Acetylation is simply the transfer of an acetyl group (CH~3~CO) onto a molecule. The acetyl group can react with a variety of atoms or functional groups on a target molecule. The atom to which the acetyl group is attached is usually denoted in the name of either the final molecule or the enzyme that performs the acetylation. Acetylation can occur with thiol groups (sulfur), hydroxyl groups (oxygen), and often amino groups (nitrogen).

Acetylation reactions can target small molecules and metabolites, or they can occur on proteins. Multiple metabolic pathways require the transfer of acetyl groups from one metabolite to the next. For example, *N*-acetylglutamate synthase catalyzes acetylation of [L]{.smallcaps}-glutamate, the first step in arginine biosynthesis ([@B43]). Acetylation of multiple aminoglycoside antibiotics has been reported to inactivate their bactericidal or bacteriostatic activity ([@B95]; [@B199]; [@B68]), and acetylation of the antibiotic chloramphenicol disables its ability to inhibit translation ([@B26]). The chitin of insects, plants, and fungi and the peptidoglycan of the bacterial cell wall are composed of complex polysaccharides ([@B14]). These polysaccharides often contain monomers such as *N*-acetylglucosamine (GlcNAc) and *N*-acetylmuramic acid (MurNAc), which are monosaccharide derivatives acetylated on the primary amine (N), as their names suggest. However, these can be further acetylated on hydroxyl groups to increase resistance to degradative enzymes, such as lysozyme and autolysins ([@B14]).

The most widely studied protein acetylations occur on amino groups, although acetylations on serine, threonine, and histidine residues of proteins also have been detected ([@B152], [@B151]; [@B168]; [@B111]). Two distinct mechanisms for acetylation of amino groups of proteins can occur: lysine acetylation (*N*𝜀-acetylation) and N-terminal protein acetylation (*N*α-acetylation). Lysine acetylation will be discussed in more detail below. *N*α-acetylation is very common in eukaryotes, but rare in bacteria with only 47 proteins detected as N-terminally acetylated in *E. coli*, 117 identified in *Pseudomonas aeruginosa*, and 145 identified in *Acinetobacter baumannii* ([@B167]; [@B97]; [@B23]). Acetylation is observed either on the free amino group of methionine or on the exposed amino acid after cleavage of the N-terminal methionine. The modification is usually co-translational in eukaryotes but post-translational in bacteria, mitochondria, and chloroplasts, as the methionine first must be deformylated ([@B173]). *N*α-acetylation has been shown to alter protein stability in eukaryotes and is typically irreversible ([@B81]; [@B82]). *E. coli* encodes three proteins that have demonstrated *N*α-acetyltransferase activity: RimI, RimJ, and RimL. Interestingly, the only known targets of RimI, RimJ, and RimL are the ribosomal proteins S5, L12, and S18, respectively ([@B266]; [@B218]). The exact physiological effects of *N*α-acetylation in *E. coli* are not known. There is evidence that RimJ plays a role in ribosome assembly, but it is not known whether this phenotype requires the *N*α-acetyltransferase activity of RimJ ([@B266]; [@B187]). RimJ also plays a role in transcriptional regulation of the P pilus of uropathogenic *E. coli*, but the specific target and whether *N*α-acetyltransferase activity is required remain unknown ([@B247]; [@B246]). One defined role for *N*α-acetylation comes from the ESAT-6 virulence factor of *Mycobacterium tuberculosis*. Cleavage of the N-terminal methionine of ESAT-6 reveals a threonine, which is then acetylated on the amino terminus. This acetylation alters protein--protein interactions with the binding partner CFP-10, which attenuates virulence ([@B166];[@B108]; [@B143]).

Until recently, the only known internal residue that could be acetylated was lysine. However, recent work from a few groups found that a family of bacterial effector molecules from certain pathogenic species can acetylate serine, threonine, and histidine in addition to lysine residues. In some *Yersinia* species, YopJ can act as an acetyltransferase to modify serine and threonine residues of kinases in mammalian host cells to subvert host immunity ([@B152], [@B151]; [@B147]; [@B168]). Similarly, HopZ3, a YopJ family member from the plant pathogen *Pseudomonas syringae*, can acetylate plant proteins on lysine, serine, threonine, and histidine residues, as well as bacterial effector proteins AvrB and AvrB3 ([@B111]). In both cases, the acetylation by YopJ or HopZ3 prevents effective immune signaling, which results in successful bacterial infection. This does not appear to be an exclusively inter-kingdom modification, because *O*-acetylation of serine and threonine was found to occur on a proteome-wide scale in *M. tuberculosis* ([@B18]). Finally, *O*-acetylation of a single serine (S608) in acetyl-CoA synthetase (Acs) regulates the ability of a neighboring lysine (K610) to be acetylated in *Streptomyces lividans* ([@B227]). The discovery of these unusual acetylated residues opens new questions concerning the prevalence of these modifications and their potential interaction with other PTMs.

*N*𝜀-Lysine Acetylation
=======================

*N*𝜀-lysine acetylation (hereafter acetylation) is the donation of an acetyl group onto the epsilon amino group of a lysine sidechain ([Figure 1](#F1){ref-type="fig"}). Acetylation increases the size of the side chain and neutralizes the positive charge (+1 to 0) when the pH is less than the pKa of the specific lysine residue. Losing the positive charge and increasing the size of lysine disrupts salt bridges and introduces steric bulk that can alter protein--protein interactions, protein--DNA interactions, stability, and enzymatic activity ([@B73]; [@B262]; [@B253]). This was first and extensively studied in the context of the histone code of eukaryotes ([@B172]), where acetylation of the lysine rich C-terminal tail reduces protein--DNA binding. This remodels chromatin to activate gene transcription ([@B2]; [@B71]; [@B235]; [@B80]). However, recent mass spectrometric studies of acetylation have detected acetylation in all three domains of life ([@B275]; [@B140]; [@B203]; [@B271]). The consortium of acetylated proteins is often called the acetylome. The first bacterial acetylome was reported in 2008 ([@B270]); since then \>50 bacterial acetylomes have been reported ([@B36]). This accumulation of bacterial acetylomes has resulted from advances in mass spectrometry-based proteomic approaches.

![Mechanisms of Acetylation. Acetylation can be catalyzed (1) by a lysine acetyltransferase (KAT) using acetyl-CoA as the acetyl donor or (2) non-enzymatically by acetyl phosphate or acetyl-CoA. Some, but not all, acetylations can be reversed by a lysine deacetylase (KDAC).](fmicb-10-01604-g001){#F1}

Mass Spectrometry-Based Proteomics to Study Bacterial Acetylomes
================================================================

Due to its high sensitivity and high-throughput, high-resolution mass spectrometry has emerged as a powerful technique to study lysine acetylation ([@B54]). For example, one can profile the global lysine acetylome of an organism, identifying acetyllysine (K^ac^) sites within a given proteome. Alternatively, one can use targeted approaches to examine specific acetyllysine sites of biological interest with high sensitivity and quantitative accuracy ([@B107]).

To compare the acetylome under different conditions, studies can be designed and mass spectrometric workflows can be optimized to not only identify K^ac^ sites, but also to detect dynamic changes in terms of relative acetylation abundance over time, in isogenic sets of mutants, or in response to different treatments. These methods have been reviewed previously ([@B27]). Such quantitative studies can be quite impactful and relevant. For example, two studies have provided insight into the dynamic changes that occur in response to the nutritional capacity of the bacterial environment ([@B105]; [@B195]). Another study characterized the acetylome of drug resistant *Salmonella* strains, identifying associations between acetylation and drug resistance ([@B113]). A recent review described how bacterial protein acetylation might mediate bacterial virulence ([@B181]). Quantitative mass spectrometric analysis of acetylation sites also has proven helpful in identifying novel lysine acetyltransferases (KATs) ([@B37]; [@B28]).

In most mass spectrometry-based workflows, such as those described above, proteins are first subjected to proteolytic digestion, and peptides are immuno-enriched with anti-K^ac^ antibodies before mass spectrometric analysis ([@B128]; [@B270]; [@B105]; [@B196], [@B195]; [@B252]). However, it is also possible to detect acetylation directly from bacterial whole lysates. For example, a large bacterial acetylation study was carried out by Nakayasu and co-workers to investigate the proteomes and acetylomes of 48 phylogenetically distant bacteria, identifying more than 9,000 acetylated proteins with approximately 190 acetylated proteins per organism, and more than 24,000 acetylated peptides with approximately 508 K^ac^ per organism ([@B154]). Many of the observed K^ac^ sites were conserved across the phylogenetic spectrum, leading the authors to conclude that lysine acetylation is an evolutionarily conserved mechanism and that bacterial cells use it to regulate central metabolism ([@B154]).

As mass spectrometric techniques and software have improved, the breadth of targets modified by acetylation has expanded. It is now clear that the extent of acetylation, the mechanisms by which acetylation occurs, the identities of acetylated proteins, and the locations of acetylation on those proteins can vary between organisms; yet, in most cases, there is great conservation in core cellular processes ([@B154]). Such approaches have shown that acetylation occurs on proteins involved in a wide diversity of cellular process, especially central metabolism and translation ([@B238]; [@B243]; [@B6]; [@B105]; [@B103]; [@B196]; [@B97]; [@B18]; [@B93]; [@B153]; [@B175]; [@B21]; [@B70]; [@B213]; [@B229]; [@B265]). As stated above, many of these acetylations are conserved. This conservation has led some to hypothesize that the mechanisms of acetylation and the consequences of those acetylations are also conserved ([@B154]).

Acetyltransferases in Bacteria
==============================

Multiple families of acetyltransferases have been discovered across phylogeny. Many of these families were discovered in relation to histone acetylation in eukaryotes. Two major families of acetyltransferases are the [G]{.ul}cn5-related *[N]{.ul}*-[a]{.ul}cetyl[t]{.ul}ransferases (GNATs) and MYST families ([@B261]; [@B234]). Two smaller groups of acetyltransferases known as the p300/CBP family and the SRC family also exist, as well as the unique acetyltransferases TAF~II~250, TFIIIC, Rtt109, and CLOCK ([@B8]; [@B150]; [@B204]; [@B139]). The kinetic mechanisms of these acetyltransferases vary. While GNATs form a ternary complex allowing a direct transfer of the acetyl group, the MYST family can either use this ternary complex mechanism or utilize a ping-pong mechanism that generates an acetylated enzyme intermediate ([@B258]). In contrast to these larger families, the p300/CBP family has been shown to use a sequential mechanism called the Theorell-Chance mechanism ([@B128]). Since GNATs are the predominant family present in bacteria, we will focus on them.

The GNATs are present across bacterial phylogeny ([@B159]) and modify a wide range of substrates, including not only proteins, but also small molecules or metabolites ([@B198]; [@B48]; [@B234]). GNATs are generally small proteins that bind acetyl-CoA (AcCoA). They have low sequence identity, but share a characteristic fold by which they are identified ([@B60]). The number of GNATs contained in a given genome can vary wildly with *Listeria monocytogenes* containing ∼14 GNATs, but *Streptomyces lividans* containing ∼72 GNATs ([@B83]).

The lysine acetylation reaction commonly occurs in a ternary complex between the substrate, AcCoA, and the GNAT, or more specifically KAT. There are three key steps to this acetylation reaction: (1) deprotonation of the target lysine, (2) nucleophilic attack of the lysine on the carbonyl carbon of the acetyl group of AcCoA, and (3) protonation and dissociation of CoA ([@B234]). Within the catalytic pocket of the KAT, there is often a catalytic glutamate that acts as a general base to deprotonate the target lysine. In the namesake Gcn5 enzyme of yeast, this glutamate is E173, which can be found conserved in many of the bacterial GNATs ([@B219]; [@B222]; [@B125]) and some MYST family members in eukaryotes ([@B258]; [@B15]). However, in the absence of this conserved glutamate, it is hypothesized that a series of residues form a water channel or "proton wire" whereby protons are carried away from active site to other residues or to the solvent ([@B58]). Once the lysine is deprotonated, it can perform a nucleophilic attack on the carbonyl carbon of AcCoA, which is bound to the KAT via a positively charged patch that coordinates the CoA moiety via its pyrophosphate and pantothenate moieties ([@B57]; [@B123]; [@B219]; [@B139]; [@B128]). The newly acetylated substrate dissociates from the KAT, but for the CoA to dissociate, it must first be protonated. Often, a tyrosine in the active site donates a proton to the thiolate of CoA.

In bacteria, GNATs were first characterized as aminoglycoside *N*-acetyltransferases ([@B251]; [@B249]). Except those that belong to the YopJ effector protein superfamily ([@B112]; [@B133]), currently every KAT discovered in bacteria belongs to the GNAT family ([@B110]; [@B221]; [@B46]). In *E. coli*, five KATs have been identified with YfiQ (also called Pat, PatZ, or Pka) being the most heavily studied ([@B238]). Homologs of YfiQ exist in many bacterial species, as described below, but additional KATs with distinctly different structures have been identified, including homologs of the other KATs in *E. coli*: RimI, YiaC, YjaB, and PhnO ([@B37]).

Deacetylases in Bacteria
========================

To make a PTM versatile and energetically efficient, the ability to add and remove the PTM is essential. Lysine acetylation can be reversed via the action of a lysine deacetylase (KDAC). Two types of deacetylases are known: NAD^+^-dependent sirtuins ([@B20]) and Zn^2+^-dependent deacetylases ([@B138]; [@B77]; [@B263]; [@B130]). Putative homologs of both families are encoded by bacteria, but only a few have been shown to function as true deacetylases ([@B84]; [@B83]).

The Zn^2+^-dependent deacetylases are simple hydrolases that cleave the acetyl group from the lysine to release acetate. The reaction requires that a conserved histidine residue act as a general base to activate a metal-bound water that attacks the carbonyl of the acetyl group. This class of deacetylase has yet to be found in *E. coli*, but AcuC of *Bacillus subtilis* ([@B67]) and LdaA of *Rhodopseudomonas palustris* ([@B41]) are family members. Enzymes of the hydrolase family can be inhibited by the addition of butyrate ([@B47]).

Sirtuins bind NAD^+^ through a Rossmann fold domain ([@B191]) and use the NAD^+^ as a co-substrate to remove acetyl groups from proteins; the products are then deacetylated lysine, nicotinamide (NAM) and 2′-*O*-acetyl-ADP-ribose. Since NAD^+^ levels are linked to nutritional status of the cell, it is thought that sirtuins allow the cell to recognize these changes and adjust acetylation accordingly ([@B248]; [@B63]). Furthermore, sirtuins may regulate their own activity by producing NAM. NAM inhibits non-competitively by condensing with an ADP-ribose-like intermediate formed during the deacetylation reaction; this condensation blocks the progression of the reaction ([@B51]) at physiological levels ([@B248]; [@B19]; [@B91]; [@B194]; [@B276]; [@B5]). NADH also competitively inhibits the reaction at physiological levels ([@B197]; [@B78]; [@B174]).

In many members of the *Enterobacteriaceae*, the sirtuin CobB exists as two isoforms. In *Salmonella enterica* and *E. coli*, a shorter isoform (CobB~S~) and the longer isoform (CobB~L~) are transcribed from two different transcription start sites ([@B223]; [@B225]). These isoforms differ by an N-terminal amphipathic stretch of 37 amino acids. Though the purpose of this N-terminal extension is unknown, both forms of the CobB protein were shown to be biologically active as deacetylases in *S. enterica* ([@B223]).

While sirtuins are classically thought of as deacetylases, it appears that they may have a broader specificity than originally thought. Sirtuins in the mitochondria have been reported to desuccinylate ([@B55]; [@B39]), demalonylate ([@B55]; [@B170]; [@B169]), dipropionate ([@B201]), deglutarylate ([@B217]), decrotonylate ([@B9]), and debutyrylate ([@B201]) lysines in addition to deacetylate. Certain human sirtuins, such as SIRT6, have a preference for removal of long-chain acyl groups from lysines. These long-chain acyl groups can be a long as 16 carbons, as in the case of palmitoylation ([@B61]). Sirtuins of archaeon *Archaeoglobus fulgidus* have similarly been shown to desuccinylate and demyristoylate peptides ([@B185]). Bacterial sirtuins have similar abilities to desuccinylate ([@B39]), dipropionate ([@B69]; [@B212]), and possibly debutyrylate ([@B255]) lysines. Many of these PTMs occur on the same lysine, possibly implicating sirtuins as a general cleanup enzyme for certain lysines. Further complicating the possible role of sirtuins, there is evidence that sirtuins can ADP-ribosylate proteins using NAD^+^ as a substrate ([@B62]).

Effects of Enzymatic Acetylation/Deacetylation on Physiology and Pathogenesis
=============================================================================

Several studies have explored the role of enzymatic acetylation on bacterial physiology, often through reverse genetics approaches where the deacetylase, acetyltransferase, or both are deleted or overexpressed. In this section, we will focus on CobB and YfiQ of *E. coli* and their homologs in *S. enterica*, as they have been studied the most extensively.

The earliest and thus most comprehensively understood roles for YfiQ and CobB are their opposing effects on the acetylation status of Acs, an enzyme that irreversibly converts acetate into AcCoA via two half reactions. Acs requires lysine 609 (K609) for the first half-reaction, which forms an acetyl-AMP intermediate ([@B205]). Thus, mutation or modification of this residue leads to a catalytically inactive enzyme ([@B205]; [@B206],[@B207]; [@B212]). Indeed, an epistasis analysis of Δ*acs*, Δ*cobB*, and Δ*yfiQ* mutants showed that regulation of Acs is essential for growth on acetate. In both *S. enterica* and *E. coli*, Δ*acs* mutants cannot grow on less than 10 mM acetate as the sole carbon source. This is due to the low affinity of the alternative Pta-AckA pathway for acetate. A Δ*cobB* mutant phenocopies a Δ*acs* mutant, while the double Δ*yfiQ*Δ*cobB* or Δ*pat*Δ*cobB* mutants can grow on less than 10 mM acetate ([@B209]; [@B30]). These results confirm that YfiQ/Pat-dependent acetylation of Acs shuts down acetate utilization through Acs and that deacetylation by CobB restores that activity ([@B205]; [@B30]). Acs was found to be regulated in the exact same fashion in more than 15 organisms tested, ranging from bacteria to humans ([Table 1](#T1){ref-type="table"}) ([@B98]). Beyond Acs, this reversible lysine acetylation has been extended to other AMP-forming acyl-CoA synthetases, which are proteins that share a similar structure and the same conserved acetylated lysine found in Acs. *R. palustris* possesses 40 of these Acs-like proteins; 10 of them are reversibly acetylated on this conserved lysine ([@B41], [@B42]). As in Acs, acetylation inactivates these enzymes.

###### 

Proteins assessed for regulation by acetylation.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Organism                        Target                                                        Target lysine(s)                         Acetylation                 Deacetylation                  Acetylation                                                                   Cite
  ------------------------------- ------------------------------------------------------------- ---------------------------------------- --------------------------- ------------------------------ ----------------------------------------------------------------------------- ----------------------------------
                                  protein                                                                                                mechanism                   mechanism                      effect                                                                        

  *Actinosynnema mirum*           Acs                                                           620                                      *Ami*PatA and 23 homologs   Not determined                 Inhibits activity                                                             [@B131]

  *Bacillus subtilis*             Acs                                                           549                                      AcuA                        AcuC, SrtN                     Abolishes activity                                                            [@B67]; [@B65], [@B66]

                                  Eno                                                           339, 390                                 *In vitro* AcP              Not determined                 Abolishes activity                                                            [@B154]

                                  HBsu                                                          3, 18, 41, 80                            YfmK                        Not determined                 Decreases DNA binding                                                         [@B28]

                                  TufA                                                          42                                       Not AcuA, not AcP           AcuC, SrtN                     No effect                                                                     [@B214]

                                  MreB                                                          240                                      Not determined              Not determined                 Reduces cell length, width, and peptidoglycan thickness                       [@B29]

                                  CshA                                                          244, 296                                 Unknown                     Not determined                 Enhances induction of SigX and SigM-dependent genes                           [@B163]; [@B164]

  *Borrelia burgdorferi*          GapA                                                          Not determined                           AcP                         Not determined                 Inhibits activity                                                             [@B21]

                                  LDH                                                           Not determined                           AcP                         Not determined                 Mixed results                                                                 [@B21]

  *Corynebacterium glutamicum*    PEPC                                                          653                                      Not determined              NCgl0616                       Inhibits activity                                                             [@B153]

  *Escherichia coli*              ArgRS                                                         126, 408                                 AcP                         CobB                           Impairs tRNA charging                                                         [@B264]

                                  CRP                                                           100                                      AcP                         Not determined                 Reduces interaction with RNAP, enhances protein stability                     [@B49]

                                  LeuRS                                                         619, 624, 809                            AcP                         CobB                           Impairs tRNA charging                                                         [@B264]

                                  Mdh                                                           99, 140                                  AcP                         CobB for 140, none for 99      Cooperatively increases activity                                              [@B59]; [@B231]

                                  RpoA                                                          291                                      AcP                         Not determined                 Reduces *cpxP* transcription                                                  [@B122]

                                  TyrRS                                                         85, 235, 238                             AcP                         CobB                           Impairs tRNA charging                                                         [@B230]

                                  RcsB                                                          154                                      AcP                         CobB                           Enhances migration, impairs acid survival                                     [@B89]; [@B31]

                                  TopA                                                          13, 45, 346, 488                         AcP                         CobB                           Reduces relaxation activity by inhibiting DNA binding and cleavage activity   [@B278], [@B277]

                                  DnaA                                                          178                                      AcP, YfiQ                   CobB                           Inhibits ATP binding                                                          [@B272]

                                  DnaA                                                          243                                      AcP, YfiQ                   CobB                           Inhibits *oriC* binding at low affinity sites                                 [@B115]

                                  CheY                                                          92, 109                                  Acs, AcCoA                  Acs, Pta, CobB                 Inhibits interaction with CheA, FliM, and CheZ\                               [@B10]; [@B11]; [@B114]; [@B119]
                                                                                                                                                                                                    Activates CheY, promotes clockwise rotation                                   

                                  YfiQ                                                          146, 149, 391, 446, 635, 819             AcCoA                       CobB                           Favors formation of octamers                                                  [@B50]

                                  Eno                                                           342, 393                                 *In vitro* AcP              Not determined                 Abolishes activity                                                            [@B154]

                                  AceA                                                          308                                      Not determined              CobB                           Inhibits activity                                                             [@B31]

                                  AlaRS                                                         73                                       Not determined              CobB                           Inhibits activity                                                             [@B225]

                                  Mat                                                           12 lysines                               Not determined              CobB (9 lysines susceptible)   Inhibits activity, may affect dimerization                                    [@B211]

                                  NhoA                                                          214, 281                                 Not determined              CobB                           Inhibits activity                                                             [@B273]

                                  RcsB                                                          180                                      *Se*Pat, *Ec*YfiQ           *Se*CobB, *Ec*CobB             Inhibits DNA binding                                                          [@B220]

                                  Acs                                                           609                                      YfiQ                        CobB                           Inhibits activity by preventing first half reaction                           [@B276]; [@B30], [@B31];

                                  protein                                                                                                mechanism                   mechanism                      effect                                                                        

                                  RNase II                                                      501                                      YfiQ                        CobB                           Inhibits RNase II activity due to reduced substrate binding                   [@B202]

                                  RNase R                                                       544                                      YfiQ                        NONE -- not CobB               Destabilizes protein                                                          [@B118]; [@B117]

                                  RpoA                                                          298                                      YfiQ                        Not determined                 Enhances *cpxP* transcription                                                 [@B121]

  *Micromonospora aurantiaca*     Acs                                                           619                                      MaKat                       Not determined                 Inhibits activity                                                             [@B257]

  *Mycobacterium bovis BCG*       Acs                                                           616                                      KATbcg (BCG_1055)           Not determined                 Abolishes activity                                                            [@B157]

                                  FadD13                                                        487                                      KATbcg (BCG_1055)           Not determined                 Inhibits activity                                                             [@B157]

  *Mycobacterium smegmatis*       FadD33                                                        511                                      *MsPat*                     MSMEG_5175                     Abolishes activity                                                            [@B232]

                                  MbtA                                                          546                                      *Ms*Pat                     Rv1151c                        Inhibits activity                                                             [@B233]

                                  PrpE                                                          586                                      *MsPat*                     Not determined                 Abolishes activity                                                            [@B256]

                                  MSMEG_4207 (USP)                                              104                                      *Mt*PatA, *Ms*PatA          Not determined                 Unknown                                                                       [@B156]

                                  Ku                                                            29, 40                                   Not determined              Not determined                 Correlates with impaired NHEJ activity                                        [@B279]

                                  HupB                                                          86                                       Not determined              Not determined                 Prevents small colony variant formation                                       [@B189]

                                  Acs                                                           589                                      PatA                        SrtN                           Impairs growth on acetate                                                     [@B79]

  *Mycobacterium tuberculosis*    DUSP16 (eukaryotic)                                           55                                       Eis                         Not determined                 Inhibits activation of JNK pathway                                            [@B99]

                                  Histone H3 (eukaryotic)                                       Not determined                           Eis                         Not determined                 Enhances binding to the IL-10 promoter                                        [@B56]

                                  HupB                                                          32                                       Eis                         Rv1151c                        Inhibits DNA binding                                                          [@B72]; [@B76]

                                  Acs                                                           617                                      *Ms*Pat                     Rv1151c, MSMEG_5175            Abolishes activity                                                            [@B254]; [@B157]; [@B161]

                                  MbtA                                                          542                                      *Ms*Pat                     Rv1151c                        Inhibits activity                                                             [@B233]

                                  DosR                                                          182                                      *Mt*Pat                     Rv1151c                        Inhibits DNA binding                                                          [@B16]; [@B259]

                                  FadD2, FadD4, FadD5, FadD10, FadD12, FadD13, FadD22, FadD35   551, 525, 519, 519, 523, 487, 480, 529   *Mt*Pat                     MSMEG_5175                     Impairs palmitoyl-AMP synthesis activity for FadD2, FadD5, and FadD15         [@B157]

                                  PtpB                                                          224                                      *Mt*Pat                     Rv1151c                        Decreases reaction rate due to reduced Vmax                                   [@B200]

                                  HspX                                                          64, 78, 85                               Not determined              Not determined                 Reduced immunogenicity                                                        [@B126]

                                  ICL1 (Rv0467)                                                 322\                                     Not determined              Not determined                 Inhibits activity (K322)\                                                     [@B252]; [@B17]
                                                                                                331\                                                                                                Enhances activity (K331)\                                                     
                                                                                                392                                                                                                 Enhances activity (K392)                                                      

                                  Histone H3 (eukaryotic)                                       9, 14                                    Rv3423.1                    Not determined                 Inhibits DNA binding by histone H3                                            [@B94]

  *Myxococcus xanthus*            Acs                                                           622                                      *Mx*Kat                     Not determined                 Inhibits activity                                                             [@B129]

  *Neisseria gonorrhoeae*         PilT                                                          117                                      AcP                         Not determined                 May contribute to membrane association,                                       [@B85]

                                  protein                                                                                                mechanism                   mechanism                      effect                                                                        

                                                                                                                                                                                                    alters microcolony formation                                                  

  *Porphyromonas gingivalis*      RprY                                                          Not determined                           *Pg*Pat                     CobB                           Inhibits DNA binding                                                          [@B116]

                                  pro-RgpB                                                      247, 248                                 VimA, PG1842                Not determined                 Permits proper processing of pro-RgpB                                         [@B146]

  *Rhodobacter sphaeroides*       FnrL                                                          175, 213, 223                            AcP                         *Rs*CobB                       Impairs transcriptional activation                                            [@B241]

  *Rhodopseudomonas palustris*    FadD                                                          546                                      *Rp*Pat                     Not determined                 Inhibits activity                                                             [@B42]

                                  HcsA                                                          524                                      *Rp*Pat                     LdaA                           Inhibits activity                                                             [@B42]

                                  LcsA                                                          499                                      *Rp*Pat                     LdaA                           Inhibits activity                                                             [@B42]

                                  PimA                                                          534                                      *Rp*Pat                     Not determined                 Inhibits activity                                                             [@B40]

                                  Acs                                                           606                                      *Rp*Pat, KatA               SrtN and LdaA                  Inhibits activity                                                             [@B41], [@B42]

                                  AliA                                                          532                                      *Rp*Pat, KatA               SrtN and LdaA                  Inhibits activity                                                             [@B41], [@B42]

                                  BadA                                                          512                                      *Rp*Pat, KatA               SrtN and LdaA                  Inhibits activity                                                             [@B41], [@B42]

                                  FcsA                                                          496                                      *Rp*Pat, KatA               LdaA                           Inhibits activity                                                             [@B42]

                                  HbaA                                                          503                                      *Rp*Pat, KatA               SrtN and LdaA                  Inhibits activity                                                             [@B41], [@B42]

                                  IbuA                                                          539                                      *Rp*Pat, KatA               LdaA                           Inhibits activity                                                             [@B42]

                                  PrpE                                                          598                                      *Rp*Pat, KatA               LdaA                           Inhibits activity                                                             [@B42]

  *Saccharomyces cerevisiae*      Pck1p                                                         514                                      Esa1                        Sir2                           Enhances activity                                                             [@B124]

  *Saccharopolyspora erythraea*   AcsA2                                                         611                                      AcP                         Not determined                 Inhibits activity by reducing affinity for acetate                            [@B268]

                                  AcsA1, AcsA2, AcsA3                                           620, 628, 615                            AcuA                        SrtN                           Inhibits activity                                                             [@B268], [@B267]

                                  GlnA1                                                         179, 357                                 AcuA                        SrtN                           Enhances GlnA1 interaction with GlnR, which enhances DNA binding affinity     [@B269]

                                  GlnA4                                                         319                                      AcuA                        SrtN                           Inhibits activity                                                             [@B269]

  *Salmonella enterica*           AceA                                                          308                                      Pat                         CobB                           Inhibits activity                                                             [@B238]; [@B42]

                                  AceK                                                          72, 83, 553                              Pat                         CobB                           Enhances activation of ICDH                                                   [@B238]; [@B42]

                                  GapA                                                          331                                      Pat                         CobB                           Enhances glycolytic activity, decreases gluconeogenesis activity              [@B238]; [@B42]

                                  HilD                                                          297                                      Pat                         Not CobB                       Enhances stability, inhibits DNA binding                                      [@B192], [@B193]

                                  PhoP                                                          201                                      Pat                         CobB                           Inhibits DNA binding                                                          [@B183]

                                  PrpE                                                          592                                      Pat                         CobB                           Abolishes activity                                                            [@B69]

                                  Lrp                                                           36                                       Pat                         CobB                           Inhibits DNA binding                                                          [@B177]

                                  Acs                                                           609                                      Pat                         CobB                           Inhibits activity by preventing first half reaction                           [@B205], [@B208]; [@B207]

                                  Charged aminoacyl tRNAs                                       Amino terminus                           TacT                        N/A                            Inhibits translation                                                          [@B33]; [@B228]

                                  protein                                                                                                mechanism                   mechanism                      effect                                                                        

                                  TacA                                                          44                                       TacT                        CobB                           Enhances TacT activity                                                        [@B228]

  *Streptomyces coelicolor*       Acs                                                           610                                      Not determined              CobB1                          Inhibits activity                                                             [@B145]

                                  GlnR                                                          142, 153, 159, 200                       Not determined              CobB2                          Alters DNA binding                                                            [@B3]

  *Streptomyces griseus*          StrM                                                          70                                       SGR1683, *Ec*YfiQ           Not determined                 Inhibits activity                                                             [@B90]

  *Streptomyces lividans*         Aacs                                                          617                                      *Sl*Pat                     *Se*CobB                       Inhibits activity                                                             [@B224]

                                  Acs                                                           610                                      *Sl*PatA, *Sl*PatB          *Sl*SrtA                       Inhibits activity                                                             [@B224]; [@B227]

  *Streptomyces venezuelae*       Acs                                                           665                                      *Sve*PatA                   Not determined                 Inhibits activity                                                             [@B131]

  *Sulfolobus solfataricus*       Alba                                                          16                                       Pat                         Sir2                           Inhibits DNA binding                                                          [@B140]

  *Thermus thermophilus*          IPMS                                                          332                                      AcCoA                       TT_C0104                       Inhibits activity                                                             [@B265]

  *Vibrio cholerae*               Acs                                                           609                                      YfiQ                        CobB                           Inhibits activity                                                             [@B120]

  *Yersinia pestis*               PhoP                                                          Not determined                           YfiQ                        CobB                           Not determined                                                                [@B127]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Other proteins have been shown to be targets of both YfiQ and CobB. For example, K501 of RNase II from *E. coli* is a target of YfiQ and CobB ([@B202]). Acetylation of K501 by YfiQ inhibits substrate binding, which results in reduced exoribonuclease activity. Treatment of RNase II with CobB restores this activity. YfiQ and CobB also reversibly acetylate K201 of PhoP from *S. enterica*. A member of a two-component regulatory system that responds to low Mg^2+^ and acid stress, Pat-dependent acetylation of K201 decreases the affinity of PhoP for its DNA binding site and thus reduces expression of PhoP-regulated genes ([@B182], [@B183]). CobB restores DNA binding by deacetylating PhoP. Finally, the highly conserved global transcriptional regulator Lrp ([@B22]; [@B142]) has been shown to be acetylated on K36 in *S. enterica*, which prevents DNA binding ([@B177]). CobB treatment permits DNA binding of Lrp.

While the mechanistic role of reversible lysine acetylation on Acs and a few other proteins is established, multiple phenotypes have been found for Δ*pat* and Δ*cobB* mutants in *S. enterica* that are not directly attributed to acetylation of a specific enzyme, but are consistent with the opposing effects of these enzymes. For example, compared to wild-type cells, a Δ*pat* mutant of *S. enterica* grows more slowly on minimal glucose but more rapidly on minimal citrate, whereas a Δ*cobB* mutant has the exact opposite phenotype ([@B238]). The Δ*pat* mutant has reduced flux through glycolysis and the TCA cycle, while a Δ*cobB* mutant again has the opposite phenotype and promotes gluconeogenesis ([@B238]). For the latter phenotype, a Δ*cobB*Δ*pat* double mutant behaves like a Δ*pat* mutant, suggesting that CobB is dispensable in the absence of acetylation via Pat, as expected if the role of CobB was simply to deacetylate Pat-dependent acetylations. Taken together, these results support the hypothesis that Pat and CobB somehow regulate central metabolism. However, the Pat- and CobB-sensitive lysines responsible for these behaviors are not known. Acetylation by Pat was reported on isocitrate lyase (AceA), isocitrate dehydrogenase (Icd), and isocitrate dehydrogenase kinase/phosphatase (AceK), and this acetylation was shown to reduce activity for each protein ([@B238]); however, these results were called into question when another group could not confirm these findings ([@B42]).

YfiQ/Pat, CobB, and their homologs also appear to be involved in certain stress responses. In contrast to the metabolic examples above, some of these effects might occur by modifying different lysines, as deletion of either enzyme sometimes does not result in opposite phenotypes. For example, when exposed to acid stress, both *E. coli* and *Yersinia pestis* have reduced survival when either *yfiQ* or *cobB* are deleted; in contrast, *S. enterica* survives better when *pat* is deleted and more poorly when *cobB* is deleted ([@B31]; [@B182]; [@B127]). When exposed to heat stress, survival of *E. coli* diminishes when *yfiQ* is deleted but increases when *cobB* is deleted ([@B134]). In contrast, *Y. pestis* survival is diminished in both Δ*cobB* and Δ*yfiQ* mutants when exposed to heat, cold, or high salt stress ([@B127]). When exposed to reactive oxygen species, the *E. coli* Δ*cobB* mutant has enhanced survival, whereas the Δ*yfiQ* mutant behaves like its wild-type parent. In a more distantly related organism, *M. tuberculosis*, loss of its sirtuin (Rv1151c) promotes growth in acidic pH ([@B17]). Finally, the acetyltransferase PatA in *Mycobacterium smegmatis* acetylates the Universal Stress Protein (MSMEG_4207) ([@B156]). Taken together, the results of these studies suggest a common role for acetylation in stress responses. The pleiotropic phenotypes of Δ*yfiQ/pat* and Δ*cobB* mutants provide evidence that the lysines they acetylate and deacetylate control a diverse set of general stress pathways.

The Regulator of Capsule Synthesis B (RcsB) can be reversibly acetylated through YfiQ and CobB *in vitro*. RcsB, a member of the two-component response regulator family, is a global transcriptional regulator of *E. coli* and *S. enterica*, regulating approximately 5 and 20% of their respective genomes ([@B176]; [@B239]). RcsB promotes capsule biosynthesis and biofilm formation, while impairing transcription of genes required for motility. In *E. coli* and *S. enterica*, RcsB is acetylated on multiple residues. One of those lysines (K180) can be acetylated *in vitro* in a YfiQ/Pat-dependent manner and deacetylated by CobB ([@B220]). K180 is found in the RcsB DNA binding motif, and acetylation of this residue reduces DNA binding, which can then be reversed by CobB. However, there is no evidence to support YfiQ/Pat as the cause of K180 acetylation *in vivo*, as mutants that delete these KATs have no obvious motility defect ([@B89]). In contrast, two independent studies found CobB to be an inhibitor of migration in *E. coli* ([@B31]; [@B64]). A Δ*cobB* mutant has more numerous and longer flagella than the parent strain, which could partially be explained by the ability of CobB to deacetylate RcsB ([@B64]).

Pat has been strongly implicated in *S. enterica* survival and infection. Pat enhances invasion of the bacteria into HeLa cells and enhances survival of the bacteria within macrophages ([@B192]). Pat also helps promote survival under acid stress, which may be partially responsible for the macrophage survival phenotype ([@B182]). Importantly, expression of the *Salmonella pathogenicity island* (SPI-1) that is required for virulence is enhanced by Pat ([@B192]). SPI-1 is controlled by transcription factor HilD, and acetylation on K297 of HilD by Pat was suggested to stabilize the protein, which could enhance SPI-1 transcription. The role of Pat in virulence was further established by infecting mice with Δ*pat* and Δ*cobB* mutants. The Δ*pat* mutants were hypovirulent and caused reduced mortality, implicating Pat and therefore acetylation as necessary for infection ([@B192]). However, Δ*cobB* mutants had little effect. The effect by Pat might be due, at least in part, to its ability to acetylate of K201 of PhoP, as a K201Q variant that mimics the constitutively acetylated isoform were hypovirulent ([@B183]). Like *S. enterica*, a Δ*yfiQ* mutant of *Yersinia pestis*, the causative agent of plague, is hypovirulent in mice ([@B127]), but unlike *S. enterica*, the Δ*cobB* mutant is equally attenuated.

The above examples demonstrate how mechanistically similar machinery has evolved in different organisms to suit their specific niches. In many cases, YfiQ/Pat and CobB act antagonistically to reversibly acetylate a specific lysine. However, in response to certain stresses, loss of either YfiQ/Pat or CobB can be detrimental to the survival of the bacterium. The pathogenicity data from *S. enterica* and *Y. pestis* suggest that, while some commonalities may exist between the requirements for acetylation in certain scenarios, there are many cases where YfiQ/Pat and CobB do not always act in opposition. These observations provide strong evidence that these enzymes can and do act independently and should not be considered a system.

Non-Enzymatic Acetylation Via AcP and AcCoA
===========================================

Whereas KAT-catalyzed acetylation has been known for some time, evidence has accumulated showing that non-enzymatic acetylation is also possible. *In vitro*, AcCoA and the bacterial metabolite acetyl phosphate (AcP) can non-enzymatically acetylate lysine residues on many proteins. *In vivo*, the impact that AcP has on the acetylome has been assessed in multiple bacteria. In the cases of *E. coli* ([@B243]; [@B105]), *B. subtilis* ([@B103]; [@B214]), and *Neisseria gonorrhoeae* ([@B175]), AcP is the predominant acetyl donor.

Chemical reactions are the basis of all life. While enzymatic catalysis is a primary driver in the kinds of substrates used and products formed, the possible chemical reactions of those substrates and products greatly exceeds those that are catalyzed ([@B74]). Many of these uncatalyzed reactions are thought to be deleterious to the cell, causing macromolecular damage, such as oxidation of DNA or proteins. Often, the damage can be caused by products of the cell's own metabolism, such as reactive oxygen species ([@B135]). Indeed, non-enzymatic modification has been implicated in multiple human diseases ([@B25]). As cells have evolved alongside this damaging potential of their own metabolism, it is not surprising that repair pathways exist to mitigate this damage. Perhaps cells have evolved ways to utilize these extra-metabolic occurrences as means to regulate their cellular processes. Specifically, in this context, we will consider acetylation via two acetyl donors, AcCoA and AcP.

The ability of AcCoA and AcP to non-enzymatically modify proteins is not a new idea. AcP has been shown to chemically acetylate amine, thiol, and hydroxyl groups ([@B52]; [@B92]). In the 1970s, it was discovered that AcP could non-enzymatically acetylate histones, albumin, and polylysine ([@B179]). Due to its high energy nature (ΔG° of -43.1 kJ/mol), which is even greater than that of AcCoA (ΔG° of -31.4 kJ/mol), AcP readily hydrolyzes in water and can acetylate without the need for an enzyme ([@B102]; [@B236]). Furthermore, the concentrations needed to achieve non-enzymatic acetylation *in vitro* are comparable to or below physiological levels, which in *E. coli* are around 300--500 μM for AcCoA and between 200 μM and 3 mM for AcP ([@B226]; [@B101]; [@B178]). *In vitro* acetylation reactions are often carried out at basic pH. Basic pH promotes deacetylation of lysine, which may prime the lysine for acetylation, but also increases the rate at which AcP and AcCoA dissociate ([@B102]; [@B52]). Susceptibility to non-enzymatic acetylation differs for each lysine and each acetyl donor used. Using glutamate dehydrogenase (GDH) as an example, it was shown a single lysine (e.g., K503) could be acetylated at different rates using two different acetyl donors, AcP and AcCoA. When comparing acetylation by a single acetyl donor, multiple lysines (e.g., K110, K415, and K503) on GDH were acetylated at different rates from one another. These *in vitro* acetylation reactions with AcP and AcCoA showed that acetylation rates of these specific lysines can vary by three orders of magnitude. Furthermore, some lysines were completely non-reactive under these conditions. These findings suggest that regulation of acetylation depends on the environmental context and thus reactivity of the lysine ([@B7]).

Assessment of non-enzymatic acetylation *in vivo* by AcCoA is difficult. In most cases, it is an essential molecule that if depleted would result in lack of viability. However, attempts to recreate the mitochondrial environment have shown that AcCoA could acetylate proteins at physiological levels *in vivo* ([@B237]). Furthermore, attempts to reduce the levels of AcCoA, such as by draining acetyl groups into an acetyl group polymer such as polyhydroxybutyrate, do not avoid any contribution by KATs ([@B88]). Work in an organism where AcCoA can be non-essential, such as the reduced genome bacterium *Borrelia burgdorferi* that solely synthesizes AcCoA to generate mevalonate, a precursor of cell wall lipid I, might be a useful reductionist system to determine whether this truly occurs *in vivo* ([@B21]). Without knowing all possible KATs and eliminating them, it is hard to truly ever say whether an AcCoA-dependent acetylation is truly non-enzymatic *in vivo*.

Fortunately, modulation or complete elimination of AcP levels is much simpler and less detrimental to many bacteria, which greatly facilitates studying AcP-dependent acetylation. In *E. coli* and many other bacteria, AcP is generated as an intermediate of the acetate fermentation pathway catalyzed by the reversible enzymes acetate kinase (AckA) and phosphotransacetylase (Pta) ([@B186]). Pta catalyzes the conversion of AcCoA and inorganic phosphate to AcP and free CoA. AckA then converts AcP into acetate by transferring the phosphoryl group to ADP to generate one molecule of ATP ([Figure 2](#F2){ref-type="fig"}). In the presence of high acetate concentrations (\>10 mM), the pathway can run in reverse, synthesizing AcCoA from acetate, ATP, and CoA ([@B24]; [@B106]). By genetically manipulating this pathway, the levels of AcP and thus acetylation can be altered. For example, if cells are grown on glucose, the cells ferment acetate and generate AcP as an intermediate. If one prevents the conversion of AcCoA to AcP by deleting Pta or the entire Pta AckA pathway, AcP cannot be generated. When these mutants are analyzed by western blot, the intensity of the acetylated proteins is greatly reduced to background levels ([@B243]; [@B105]). It is worth noting that acetylation can still be detected by mass spectrometry in Δ*pta* and Δ*pta ackA* mutants, but the relative amount of acetylation and number of acetylated lysines is greatly reduced. On the other hand, by deleting *ackA*, AcP accumulates to 10--20 mM ([@B101]; [@B250]; [@B243]), which can be seen via western blot as a greatly intensified acetylation profile relative to wild-type cells ([@B243]; [@B105]). Mass spectrometry confirms that many more unique lysines on many more unique proteins become acetylated in this mutant, and those lysines that are detected as acetylated in wild-type become further acetylated as the proportion of the total pool of each unique peptide shifts toward acetylated ([@B243]; [@B105]).

![The Pta-AckA acetate fermentation pathway generates AcP as an intermediate. Phosphotransacetylase (Pta) converts AcCoA to AcP by substituting CoA for inorganic phosphate (P~i~). Acetate kinase (AckA) converts AcP to acetate, generating an ATP in the process. This pathway is reversible.](fmicb-10-01604-g002){#F2}

Targets of Non-Enzymatic, AcP-Dependent Acetylation
===================================================

To date, only a handful of groups have tried to directly determine the impact of acetylation by AcP on the acetylome of an organism ([@B243], [@B245]; [@B105]; [@B175]; [@B21]; [@B184]). This has been achieved by mass spectrometry analysis of wild-type cells and comparing the acetylated proteins to acetylated proteins cells where the levels of AcP have been manipulated, usually by deleting *ackA* to accumulate AcP in cells or by deleting *pta* to prevent synthesis of AcP. Due to the prevalence of AcP-dependent acetylation, especially under conditions when cells are exposed to high carbon concentrations, much of the acetylation detected in wild type bacteria is likely a result of acetylation by AcP ([@B196]).

These studies result in large data sets with hundreds of lysines acetylated from multiple organisms. Often, to get a picture of what processes these acetylated lysines may be involved in, the modified proteins can be grouped by keyword enrichment, gene ontology term enrichment, and Kegg pathway enrichment. Across these studies and grouping strategies, the modified proteins fall into multiple processes, but the two most common are translation and central metabolism.

From the current *E. coli* data sets, it appears that most of the ribosomal subunits, most of the aminoacyl-tRNA ligases, and all of the elongation factors are acetylated on multiple lysines in an AcP-dependent manner. In contrast, AcP acetylates only one lysine on one initiation factor ([@B105]; [@B196]). Whether any of these acetylations impact the rate or fidelity of translation has yet to be determined. However, it has been shown that charging of tRNAs can be inhibited by AcP-dependent acetylation of certain aminoacyl-tRNA ligases ([@B230]; [@B264]).

Similarly, most central metabolic enzymes are acetylated in an AcP-dependent manner; this is true for all of the glycolytic pathways of *E. coli* and *B. subtilis* (i.e., Embden--Meyerhof--Parnas, Pentose Phosphate, and Entner--Doudoroff). Currently, the functional consequences of most of these acetylations remain largely undetermined. However, it is reported that AcP-dependent acetylation abolishes the activity of the glycolytic enzyme enolase from both *E. coli* and *B. subtilis* ([@B154]) and inhibits the activity of glyceraldehyde 3-phosphate dehydrogenase A from *Borrelia burgdorferi* ([@B21]). The TCA cycle is also highly acetylated by AcP. Thus far, malate dehydrogenase is the rare example of a central metabolic enzyme whose activity is enhanced by AcP-dependent acetylation ([@B231]).

Structural Determinants of Non-Enzymatic Acetylation
====================================================

While non-enzymatic acetylation does not require a KAT, analysis of the environments that contain acetylated lysines suggest that the mechanism by which this enzyme-independent reaction occurs has many parallels with enzymatic acetylation ([Figure 3](#F3){ref-type="fig"}). While the KAT serves as an AcCoA-binding protein to properly position the acetyl group near the target lysine, non-enzymatic acetylation requires that the protein being acetylated coordinates the CoA group for AcCoA or the phosphate moiety for AcP ([@B105]). Often, the coordinating amino acids are positively charged (Arg and Lys), which make ionic bonds, or polar amino acids that make hydrogen bonds via hydroxyl groups (Ser, Thr, and Tyr) or side chain amides (Gln and Asn) ([@B105]). In contrast to KAT-dependent acetylation, where a glutamate from the KAT typically extracts a proton from the lysine to be acetylated, during non-enzymatic acetylation, the non-enzymatic process requires an internal glutamate or a water molecule ([@B165]; [@B105]). It may be expected that lysines acetylated non-enzymatically may have a reduced pK~a~, and thus more propensity to lose a proton. However, the pK~a~ has not been found to correlate with reactivity ([@B7]). Like KATs and KDACs, there is no clear motif that is predictive of whether a lysine is susceptible to chemical acetylation. This was shown by using AcP to acetylate a peptide library with the sequence GXKZGC, where X and Z are each a standard amino acid with the exception of cysteine, on a SAMDI chip. This method showed that almost every peptide could be acetylated, but selectivity and specificity could be achieved by adding magnesium and salt ([@B105]). The SAMDI results indicated adjacent arginines and lysines favored acetylation; *in vivo*, however, there is a propensity for glutamates and aspartates to be adjacent to the lysines acetylated by AcP. Similar results were found for AcCoA, where glutamates were found near lysines *in vivo* ([@B7]). For both AcP and AcCoA, there is a tendency for susceptible lysines to be surface-exposed ([@B105]; [@B7]). However, due to their relatively small size, AcP and AcCoA can access buried lysines that a KAT could not ([@B105]). Thus, protein structures could have evolved to utilize non-enzymatic acetylation for roles that are impossible for enzymatic acetylation.

![Catalytic mechanisms of enzymatic and non-enzymatic acetylation. **(Top)** In the enzymatic mechanism, a lysine to be acetylated binds at the acceptor site of a lysine acetyltransferase (KAT) and AcCoA binds at the donor site of the KAT called the P-loop (red) with consensus motif Gln/Arg-x-x-Gly-x-Gly/Ala ([@B190]). A catalytic glutamate deprotonates the epsilon amino group of the target lysine. The lysine performs a nucleophilic attack on the carbonyl carbon of AcCoA, resulting in acetylation of the lysine. The CoA group becomes protonated by a tyrosine, which regenerates the KAT and facilitates the release of the free CoA and the target protein. **(Bottom)** In this example of non-enzymatic acetylation, AcP is bound through its negatively charged phosphoryl group to a neighboring patch (yellow) that contains positively charged residues and/or residues that can form hydrogen bonds. In this example, the lysine is deprotonated by a glutamate on the same protein. The lysine performs a nucleophilic attack on the carbonyl carbon of AcP resulting in an acetyllysine. Inorganic phosphate is released as a byproduct of the reaction. A mechanism similar to this can be considered for non-enzymatic AcCoA-dependent acetylation.](fmicb-10-01604-g003){#F3}

Regulation of AcP-Dependent Acetylation -- a Consequence of Fermentation
========================================================================

When the glucose consumption rate depletes free CoA faster than it can be recycled, *E. coli* will ferment acetate from AcCoA via the Pta-AckA pathway ([Figure 4](#F4){ref-type="fig"}). This occurs even in the presence of oxygen in a process called overflow metabolism, akin to a safety valve that regenerates the limiting pools of CoA ([@B86]; [@B4]). However, the production of AcP by Pta is faster than the conversion of AcP to acetate by AckA, leaving a pool of the intermediate AcP ([@B101]; [@B96]). Thus, when *E. coli* cells are grown in the presence of excess carbon such as glucose, the bacteria ferment acetate and produce AcP. Thus, ameliorating the need for cells to ferment reduces acetylation. Such an example is when cells lacking the major glucose transporter EIICB^glc^ are grown in medium supplemented with glucose. These mutants must assimilate glucose through alternative glucose transporters such as the galactose permease GalP. The use of these alternative transporters reduces the rate of glucose flux into the cell. As such, the cells also produce less acetate and, as expected, have reduced acetylation ([@B210]; [@B196]).

![AcP is made as a consequence of overflow metabolism. **(Left)** When bacteria like *E. coli* are growing on low concentrations of carbon, much of the carbon is put into the TCA cycle, lipid metabolism, and metabolite biosynthesis. Acetate production is very low. **(Right)** When the concentration of carbon increases, the flux of carbon through glycolysis depletes the limiting pool of free CoA. To continue to consume carbon, *E. coli* can regenerate free CoA by fermenting acetate. This results in the production of AcP.](fmicb-10-01604-g004){#F4}

This phenomenon is not exclusive to glucose. Lactate, fructose, and xylose can also potently induce acetylation in *E. coli* as assessed by anti-acetyllysine western blot ([@B196], [@B195]; [@B35]). Mass spectrometric analysis has determined the acetylomes of cells grown in xylose, a pentose sugar, and cells grown in glucose, a hexose sugar ([@B195]). Glucose and xylose are catabolized through different metabolic pathways; however, each pathway results in acetate fermentation. As such, it may not be surprising that, regardless of carbon source, almost every acetylated lysine was similarly regulated in glucose or xylose. The one exception was xylose isomerase, a protein necessary for catabolism of xylose, which had two lysines differentially acetylated in glucose and xylose. These results suggest that cells regulate AcP-dependent acetylation simply by regulating overflow metabolism and production of AcP.

One other key physiological shift that causes accumulation of acetylations is cessation of growth, such as entry into stationary phase. For both *E. coli* and *N. gonorrhoeae*, acetylation increased as the culture entered stationary phase either naturally or when artificially induced ([@B243]; [@B105]; [@B196]; [@B175]). We recently determined why acetylation accumulates after *E. coli* cultures enter into stationary phase. *E. coli* cultures grown in glucose-supplemented peptide-based media consume both amino acids and glucose during exponential growth; however, most of the glucose is consumed after the culture enters into stationary phase ([@B38]).

Compared to exponential phase, two facets of stationary phase make it the perfect growth phase to promote acetylation when excess carbon is present: reduced protein synthesis and reduced respiration. In stationary phase, rates of growth cannot be sustained due to depletion of a limiting nutrient ([@B180]). Thus, cells reduce rates of transcription and translation, which greatly reduces the generation of new proteins ([@B158]). Since the rate of protein biosynthesis is reduced, fewer TCA cycle intermediates are used to generate new biomass. This will cause a bottleneck at the TCA cycle, and carbon must enter other pathways. In conjunction with reduced translation, total cellular protein becomes further reduced due to increased protein turnover. When *E. coli* enters stationary phase, aerobic metabolism is repressed ([@B162]; [@B158]). As such, the carbon flux is driven toward fermentation. The combination of a reduced proteome in stationary phase and the continued metabolism of a fermentable carbon source increase the probability that any susceptible lysine will become acetylated.

In conclusion, data thus far suggests that non-enzymatic AcP-dependent acetylation is an unavoidable consequence of fermentation that accumulates on an aging proteome. Since AcP is made as an intermediate of fermentation, the only means of regulating acetylation would be by regulating fermentation, deacetylation of acetyllysines with a KDAC, and/or evolving protein structures to optimally favor/disfavor acetylation of specific lysines. Because acetate fermentation has evolved as a key mechanism that allows many bacteria to regenerate the limited pool of CoA, this would suggest that *E. coli* has evolved over millions of years to cope with or utilize this global modification.

A Possible Evolutionary History of Acetylation and Because of Acetylation
=========================================================================

Because nearly all life has evolved to utilize activated acetate as a key molecule in metabolism, all organisms must inevitably cope with the potential for protein acetylation. To understand the physiological relevance of acetylation, it is helpful to first imagine how acetylation evolved. As proposed previously, AcP is a relatively simple molecule compared to ATP or AcCoA with higher energy, and as such is likely to be a more ancient energy currency ([@B160]; [@B250]). Due to the well-understood effects of phosphorylation by AcP, it was proposed that proteins like response regulators could have evolved to accept phosphoryl groups from AcP, and only later would the cell have evolved phosphatases to remove those phosphoryl groups. Finally, some phosphatases would evolve to become kinases to fine-tune these pathways ([@B250]).

Similarly, the ability for AcP to acetylate proteins also could be a driver of evolution. Acetylation of a catalytic lysine can be extremely detrimental to protein function, and inability to remove these acetylations could result in a dead enzyme. Thus, cells must have evolved deacetylases to ensure that a given lysine would be unmodified despite the presence of endogenously produced reactive metabolites. Contrary to the phosphorylation example, the acetyltransferases are not homologous to the deacetylases and must have evolved independently. Perhaps these acetyltransferases evolved after the development of their primary substrate, AcCoA.

Each acetylated lysine has the potential to be regulatory. Whether these acetylations are due to non-enzymatic mechanisms or catalyzed enzymatically, life must balance the possibility of detrimental acetylation with benign or beneficial acetylations. The best ways to ensure that only optimal lysines are acetylated under a given condition would be to either (1) evolve a lysine deacetylase to remove deleterious modifications or (2) evolve proteins such that they do not have critical lysines susceptible to acetylation. For *E. coli*, almost all acetylated linear peptides are susceptible to CobB ([@B1]), but not all acetylated *E. coli* proteins are CobB-sensitive *in vivo* ([@B105]). The CobB-sensitive lysines tend to be surface-exposed ([@B1]). Indeed, for a lysine to be deacetylated, it almost certainly cannot be buried within the protein structure, unless the acetylated residue becomes accessible through "protein breathing," large scale conformational changes of the protein structure ([@B104]). However, the extent of breathing *in vivo* is probably restricted due to molecular crowding in the cytoplasm ([@B137]). Thus, the protein must be structured in such a way to favor deacetylation of the target lysine without disrupting the activity of the protein.

If an acetylated lysine blocks protein function and is not accessible to CobB or another deacetylase, the cell must replace that protein by degrading it and synthesizing an entirely new protein. Not all lysines can be acetylated, but those that do become modified can be acetylated at different rates ([@B7]; [@B196]). As buried lysines would be refractory to CobB, one would also expect that acetylation of these lysines is rarely enzymatic due to the inability for an enzyme to access the lysine. Thus, evolution may have selected for molecular environments that disfavor acetylation of these buried and other critical lysines. However, any changes made over evolution that would disfavor acetylation had to be balanced with a protein sequence that permits proper folding and activity.

Future Thoughts
===============

The study of acetylation is a fast growing field with technological advances in analytical methodologies, such as mass spectrometry, providing a greater depth of analysis. The report of each new acetylome opens more avenues to explore. While some acetylations are certain to be organism-specific, there are bound to be many conserved acetyllysines in critical processes, as we have already observed in central metabolism and translation. Each of these acetyllysines must result from one or more of the recognized acetylation mechanisms, either enzymatic or non-enzymatic. In turn, these mechanisms may themselves be regulated dynamically with the potential for signaling cascades akin to phosphorylation.

Researchers in this new field have two main routes that they can follow. They can investigate the effect of acetylation on individual sites on individual proteins or they can study the effect of global acetylation. The former route can take advantage of the numerous acetylome studies that have yielded data sets containing hundreds of acetylated proteins modified on thousands of unique lysines. The problem is how to prioritize the most functionally relevant acetylation sites. Typically, researchers prioritize by choosing lysines in provocative locations on proteins with easily assessed phenotypes or activities. However, it should be noted that genetic mimic/genetic ablative mutants are often used to compare extreme stoichiometries, i.e., a mimic of the 100% acetylated state versus a mimic of the 100% unacetylated state. The same is true of proteins acetylated by non-canonical amino acid substitution.

Another way to prioritize is to determine the stoichiometry of each acetylated lysine ([@B6]; [@B155]; [@B242], [@B245]; [@B144]; [@B148]; [@B240]). A lysine with a large fold change but a low basal stoichiometry may be a less physiologically important acetylation event compared to one with a smaller fold change but a higher basal stoichiometry. Unfortunately, obtaining the stoichiometry of the acetylome is a non-trivial technical challenge for all but a few groups. To make matters worse, most of the existing analyses were performed on highly mutagenized laboratory strains grown under conditions that make physiologically relevant interpretations difficult.

Whereas site-specific or protein-specific investigations can provide lessons concerning the manner in which acetylation influences protein structure/function relationships, such focused studies cannot explain the global effect of simultaneous low stoichiometric acetylation of large numbers of lysines, as occurs by non-enzymatic acetylation. These acetylations greatly expand the acetylome, neutralizing thousands of positive charges, yet the impact of these modifications remains unclear. Furthermore, acetylation is not the only global modification. The proteome can be acylated using many other central metabolites that may compete for the same lysines ([@B170]; [@B274]; [@B39]; [@B237]; [@B244]; [@B103]; [@B200]; [@B260]; [@B144]; [@B149]; [@B212]; [@B12]; [@B70]; [@B229]; [@B240]). The potential crosstalk amongst these acylations and between these acylations and other PTMs presents an important challenge as we attempt to truly understand the inner workings of the cell.

Since lysines can be acylated without the use of an enzyme, we would suspect that bacteria would have evolved to utilize this otherwise "wasteful" process. We propose that global acylation may serve many functions. For example, acylations may serve as a feedback mechanism to slow an excessive carbon flux. Acylations could protect proteins against damaging modifications, such as carbonylation, that result in protein misfolding and aggregation ([@B45]; [@B136]). Acylations may be less severe modifications that could protect proteins against such harmful lesions. It may also be possible for acetylation to serve as a method for cells to store two carbon subunits. While there are designated carbon storage polymers, such as starch in plants or glycogen in animals, fungi, and bacteria, perhaps acetylation is a primordial form of carbon storage.

Finally, researchers should remember that heterologous expression of a protein in *E. coli* or any other bacterium carries the possibility that the purified protein preparation may be a heterogeneous mixture decorated by various acylations. Indeed, at least one group has reported that recombinant insulin produced in *E. coli* is acetylated ([@B215]). The potential for acylations to influence efficacy has great implications for the pharmaceutical industry, but also for any researcher who uses a heterologous system to express their protein of interest. Depending on the protein and the conditions under which the host bacteria are grown, the modified protein may behave in a manner that is not consistent with expectations.
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